数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Arndt Rolfs Director, Chief Executive Officer 60 未披露 未持股 2020-04-23
Dirk H. Ehlers Director, Chief Operating Officer 59 未披露 未持股 2020-04-23
Richard Stoffelen Director, Chief Financial Officer 52 未披露 未持股 2020-04-23
Volkmar Weckesser Director, Chief Information Officer 52 未披露 未持股 2020-04-23
Christoph Ehlers Member of the Supervisory Board 62 未披露 未持股 2020-04-23
Holger Friedrich Member of the Supervisory Board 53 未披露 未持股 2020-04-23
Guido Prehn Member of the Supervisory Board 42 未披露 未持股 2020-04-23
Eric Souetre Member of the Supervisory Board 64 未披露 未持股 2020-04-23
Peer M. Schatz Interim Member and Vice-Chairman of the Supervisory Board 54 未披露 未持股 2020-04-23
Hubert Birner Member of the Supervisory Board 53 未披露 未持股 2020-04-23
Flemming Ornskov Chairman of the Supervisory Board 62 未披露 未持股 2020-04-23
Berndt Modig Member of the Supervisory Board 61 未披露 未持股 2020-04-23

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Arndt Rolfs Director, Chief Executive Officer 60 未披露 未持股 2020-04-23
Dirk H. Ehlers Director, Chief Operating Officer 59 未披露 未持股 2020-04-23
Richard Stoffelen Director, Chief Financial Officer 52 未披露 未持股 2020-04-23
Volkmar Weckesser Director, Chief Information Officer 52 未披露 未持股 2020-04-23
Oved Amitay Chief Business Officer 54 未披露 未持股 2020-04-23
Peter Bauer Chief Genomic Officer 50 未披露 未持股 2020-04-23
Sun Kim Chief Strategy & Investor Relations Officer 48 未披露 未持股 2020-04-23
Philip Lambert Chief Scientific Officer 52 未披露 未持股 2020-04-23

董事简历

中英对照 |  中文 |  英文
Arndt Rolfs

Arndt Rolfs是我们的联合创始人之一。他自2014年起担任首席执行官,自2006年起担任首席医疗官。他此前曾于2008年至2018年担任罗斯托克大学阿尔布雷希特-科塞尔神经再生研究所所长。在创立Centogene之前,Rolfs教授从1997年到2008年担任罗斯托克大学神经学中心临床和门诊神经科副主任。他也曾担任the Department of Neurology的高级顾问,以及the University of Rostock的神经生物学研究实验室的负责人(从1993年到2008年)。从1991年到1993年,他曾任职柏林the University Hospital Rudolf-Virchow的精神病诊所。从1989年到1993年,他是柏林自由大学(the Free University of Berlin)神经化学实验室的负责人。Rolfs从1988年到1989年在Max-Planck-Institute for Molecular Genetics任职,从1985年到1988年在柏林自由大学(Free University of Berlin)神经学系任职。Rolfs教授是罕见病领域几个国际流行病学研究的首席研究员,并积极从事几种代谢性疾病的生物标志物研究。他在医学和科学出版物方面有着广泛的往绩记录,是300多份同行评议出版物的作者或贡献者。Rolfs教授于1985年获得美因茨大学(the University of Mainz)的医生认可。


Arndt Rolfs is one of our co-founders. He has served as Chief Executive Officer since 2014 and Chief Medical Officer since 2006. He previously served as Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock from 2008 to 2018. Prior to founding Centogene, Prof. Rolfs was Vice-Director of the Clinic and Outpatients Department for Neurology at the Centre for Neurology, University of Rostock, from 1997 to 2008. He also served as a Senior Consultant at the Department of Neurology and as Head of the Neurobiological Research Laboratory from 1993 to 2008 at the University of Rostock. From 1991 to 1993 he worked at the Psychiatric Clinic at the University Hospital Rudolf-Virchow in Berlin. From 1989 to 1993 he was the Head of the Laboratory for Neurochemistry at the Free University of Berlin. From 1988 to 1989 Prof. Rolfs worked at the Max-Planck-Institute for Molecular Genetics and from 1985 to 1988 at the Department of Neurology at the Free University of Berlin. Prof. Rolfs is the principal investigator of several international epidemiological studies in the area of rare diseases and actively engaged in biomarker research for several metabolic diseases. He has an extensive track record in medical and scientific publications and is the author of or contributor to more than 300 peer-reviewed publications. Prof. Rolfs received his approbation as physician from the University of Mainz in 1985.
Arndt Rolfs是我们的联合创始人之一。他自2014年起担任首席执行官,自2006年起担任首席医疗官。他此前曾于2008年至2018年担任罗斯托克大学阿尔布雷希特-科塞尔神经再生研究所所长。在创立Centogene之前,Rolfs教授从1997年到2008年担任罗斯托克大学神经学中心临床和门诊神经科副主任。他也曾担任the Department of Neurology的高级顾问,以及the University of Rostock的神经生物学研究实验室的负责人(从1993年到2008年)。从1991年到1993年,他曾任职柏林the University Hospital Rudolf-Virchow的精神病诊所。从1989年到1993年,他是柏林自由大学(the Free University of Berlin)神经化学实验室的负责人。Rolfs从1988年到1989年在Max-Planck-Institute for Molecular Genetics任职,从1985年到1988年在柏林自由大学(Free University of Berlin)神经学系任职。Rolfs教授是罕见病领域几个国际流行病学研究的首席研究员,并积极从事几种代谢性疾病的生物标志物研究。他在医学和科学出版物方面有着广泛的往绩记录,是300多份同行评议出版物的作者或贡献者。Rolfs教授于1985年获得美因茨大学(the University of Mainz)的医生认可。
Arndt Rolfs is one of our co-founders. He has served as Chief Executive Officer since 2014 and Chief Medical Officer since 2006. He previously served as Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock from 2008 to 2018. Prior to founding Centogene, Prof. Rolfs was Vice-Director of the Clinic and Outpatients Department for Neurology at the Centre for Neurology, University of Rostock, from 1997 to 2008. He also served as a Senior Consultant at the Department of Neurology and as Head of the Neurobiological Research Laboratory from 1993 to 2008 at the University of Rostock. From 1991 to 1993 he worked at the Psychiatric Clinic at the University Hospital Rudolf-Virchow in Berlin. From 1989 to 1993 he was the Head of the Laboratory for Neurochemistry at the Free University of Berlin. From 1988 to 1989 Prof. Rolfs worked at the Max-Planck-Institute for Molecular Genetics and from 1985 to 1988 at the Department of Neurology at the Free University of Berlin. Prof. Rolfs is the principal investigator of several international epidemiological studies in the area of rare diseases and actively engaged in biomarker research for several metabolic diseases. He has an extensive track record in medical and scientific publications and is the author of or contributor to more than 300 peer-reviewed publications. Prof. Rolfs received his approbation as physician from the University of Mainz in 1985.
Dirk H. Ehlers

DirkH.Ehlers自2018年4月起担任Clinical Diagnostics首席运营官兼总裁。加入我们之前,他曾担任伊利诺伊州芝加哥希尔罗控股公司的高级副总裁和外科解决方案部门总裁,以及集团执行团队成员。2015年至2018年,他是Protagen AG的非执行董事会成员。从2010年到2014年,Ehlers博士担任Eppendorf AG的总裁兼首席执行官。在此之前,他从2007年到2010年担任Hoffmann La Roche专业诊断主管和诊断执行委员会成员。从2001年到2007年,他是Evotec AG的首席财务官和执行董事会成员。从2000年到2001年,Ehlers博士担任Fresenius Kabi AG的执行董事会成员兼肠内营养部总裁。从1995年到2000年,他担任Olympus Europe的诊断系统部门主管。从1989年到1994年,他是麦肯锡公司(McKinsey&Co.)的管理顾问和业务经理。Inc.Ehlers博士拥有硕士学位。他以优异成绩获得亚琛RWTH大学物理学博士学位和物理学博士学位,成绩优异。


Dirk H. Ehlers has served as chief operating officer and president of Clinical Diagnostics since April 2018. Prior to joining us, he served as senior vice president and president of the Surgical Solutions Division and as a member of the Group Executive Team at Hill-Rom Holdings, Inc. in Chicago, Illinois. From 2015 to 2018 he was a non-executive board member of Protagen AG. From 2010 to 2014 Dr. Ehlers served as president and CEO of Eppendorf AG. Prior to that, he served as head of Professional Diagnostics and as a member of the Diagnostics Executive Committee at Hoffmann La Roche from 2007 to 2010. From 2001 to 2007 he was chief financial officer and an executive board member of Evotec AG. From 2000 to 2001 Dr. Ehlers served as an Executive Board member and president of the Enteral Nutrition Division of Fresenius Kabi AG. From 1995 to 2000 he served as Diagnostic Systems Division head at Olympus Europe. From 1989 to 1994 he was a management consultant and an engagement manager at McKinsey & Co. Inc. Dr. Ehlers holds a M.Sc. in Physics and received his Ph.D. in Physics with distinction, summa cum laude, both from the University RWTH in Aachen.
DirkH.Ehlers自2018年4月起担任Clinical Diagnostics首席运营官兼总裁。加入我们之前,他曾担任伊利诺伊州芝加哥希尔罗控股公司的高级副总裁和外科解决方案部门总裁,以及集团执行团队成员。2015年至2018年,他是Protagen AG的非执行董事会成员。从2010年到2014年,Ehlers博士担任Eppendorf AG的总裁兼首席执行官。在此之前,他从2007年到2010年担任Hoffmann La Roche专业诊断主管和诊断执行委员会成员。从2001年到2007年,他是Evotec AG的首席财务官和执行董事会成员。从2000年到2001年,Ehlers博士担任Fresenius Kabi AG的执行董事会成员兼肠内营养部总裁。从1995年到2000年,他担任Olympus Europe的诊断系统部门主管。从1989年到1994年,他是麦肯锡公司(McKinsey&Co.)的管理顾问和业务经理。Inc.Ehlers博士拥有硕士学位。他以优异成绩获得亚琛RWTH大学物理学博士学位和物理学博士学位,成绩优异。
Dirk H. Ehlers has served as chief operating officer and president of Clinical Diagnostics since April 2018. Prior to joining us, he served as senior vice president and president of the Surgical Solutions Division and as a member of the Group Executive Team at Hill-Rom Holdings, Inc. in Chicago, Illinois. From 2015 to 2018 he was a non-executive board member of Protagen AG. From 2010 to 2014 Dr. Ehlers served as president and CEO of Eppendorf AG. Prior to that, he served as head of Professional Diagnostics and as a member of the Diagnostics Executive Committee at Hoffmann La Roche from 2007 to 2010. From 2001 to 2007 he was chief financial officer and an executive board member of Evotec AG. From 2000 to 2001 Dr. Ehlers served as an Executive Board member and president of the Enteral Nutrition Division of Fresenius Kabi AG. From 1995 to 2000 he served as Diagnostic Systems Division head at Olympus Europe. From 1989 to 1994 he was a management consultant and an engagement manager at McKinsey & Co. Inc. Dr. Ehlers holds a M.Sc. in Physics and received his Ph.D. in Physics with distinction, summa cum laude, both from the University RWTH in Aachen.
Richard Stoffelen

Richard Stoffelen自2016年起担任首席财务官“首席财务官”。他在专注于金融、治理和风险管理的国际角色方面拥有超过30年的经验。加入我们之前,他曾担任Holcim Group Services公司的内部审计主管(2013年至2016年)。从2000年到2013年,他曾担任KPMG公司的多种审计和管理职务,在那里他曾负责多种行业的客户审计,包括制药行业。Stoffelen先生毕业于荷兰NBA和蒂尔堡大学(Tilburg University)的荷兰特许会计师,并在哈佛商学院(Harvard Business School),欧洲工商管理学院(INSEAD),国际管理发展学院(IMD)和IESE商学院(IESE Business School)进修高管教育课程。


Richard Stoffelen has served as chief financial officer "CFO" since 2016. He has over 30 years of experience in international roles focused on finance, governance and risk management. Prior to joining us, he was head of Internal Audit at Holcim Group Services from 2013 to 2016. From 2000 to 2013 Mr. Stoffelen worked in various audit and management positions as a partner at KPMG, where he was responsible for audits of clients in a wide variety of industries, including the pharmaceutical industry. Mr. Stoffelen graduated as a Dutch chartered accountant with the NBA and Tilburg University in the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), the IMD and the IESE business school.
Richard Stoffelen自2016年起担任首席财务官“首席财务官”。他在专注于金融、治理和风险管理的国际角色方面拥有超过30年的经验。加入我们之前,他曾担任Holcim Group Services公司的内部审计主管(2013年至2016年)。从2000年到2013年,他曾担任KPMG公司的多种审计和管理职务,在那里他曾负责多种行业的客户审计,包括制药行业。Stoffelen先生毕业于荷兰NBA和蒂尔堡大学(Tilburg University)的荷兰特许会计师,并在哈佛商学院(Harvard Business School),欧洲工商管理学院(INSEAD),国际管理发展学院(IMD)和IESE商学院(IESE Business School)进修高管教育课程。
Richard Stoffelen has served as chief financial officer "CFO" since 2016. He has over 30 years of experience in international roles focused on finance, governance and risk management. Prior to joining us, he was head of Internal Audit at Holcim Group Services from 2013 to 2016. From 2000 to 2013 Mr. Stoffelen worked in various audit and management positions as a partner at KPMG, where he was responsible for audits of clients in a wide variety of industries, including the pharmaceutical industry. Mr. Stoffelen graduated as a Dutch chartered accountant with the NBA and Tilburg University in the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), the IMD and the IESE business school.
Volkmar Weckesser

Volkmar Weckesser自2016年起担任首席信息官。加入我们之前,他曾担任Gothaer Systems GmbH的首席执行官兼集团首席信息官(2014年至2016年)。他曾担任执行委员会成员2009年至2014年担任DeKabank Deutsche Girozentrale的信息技术主管从2003年到2009年担任HSH Nordbank AG信息技术部门的中央部门经理,从1999年到2003年担任Landesbank Schleswig-Holstein Girozentrale的部门经理,从1998年到1999年担任Deutsche Apotheker und&196;RTZebank EG的首席执行官个人助理Mitchell Madison Group的项目经理1996年至1998年Monitor Company顾问和项目经理(1993年至1996年)和Universitat Karlsruhe讲师(1991年至1993年)。他持有Universitat Karlsruhe的博士学位。


Volkmar Weckesser has served as chief information officer since 2016. Prior to joining us, he served as chief executive officer and group chief information officer at Gothaer Systems GmbH from 2014 to 2016. He served as a Member of the Executive Council and head of Information Technology at Dekabank Deutsche Girozentrale from 2009 to 2014 as a central division manager of the Information Technology Division of HSH Nordbank AG from 2003 to 2009 division manager of Landesbank Schleswig-Holstein Girozentrale from 1999 to 2003 personal assistant to the CEO at Deutsche Apotheker und Ärtzebank EG from 1998 to 1999 project manager at Mitchell Madison Group from 1996 to 1998 consultant and project manager at Monitor Company from 1993 to 1996 and lecturer at Universitat Karlsruhe 1991 to 1993. He holds a Ph.D. from Universitat Karlsruhe.
Volkmar Weckesser自2016年起担任首席信息官。加入我们之前,他曾担任Gothaer Systems GmbH的首席执行官兼集团首席信息官(2014年至2016年)。他曾担任执行委员会成员2009年至2014年担任DeKabank Deutsche Girozentrale的信息技术主管从2003年到2009年担任HSH Nordbank AG信息技术部门的中央部门经理,从1999年到2003年担任Landesbank Schleswig-Holstein Girozentrale的部门经理,从1998年到1999年担任Deutsche Apotheker und&196;RTZebank EG的首席执行官个人助理Mitchell Madison Group的项目经理1996年至1998年Monitor Company顾问和项目经理(1993年至1996年)和Universitat Karlsruhe讲师(1991年至1993年)。他持有Universitat Karlsruhe的博士学位。
Volkmar Weckesser has served as chief information officer since 2016. Prior to joining us, he served as chief executive officer and group chief information officer at Gothaer Systems GmbH from 2014 to 2016. He served as a Member of the Executive Council and head of Information Technology at Dekabank Deutsche Girozentrale from 2009 to 2014 as a central division manager of the Information Technology Division of HSH Nordbank AG from 2003 to 2009 division manager of Landesbank Schleswig-Holstein Girozentrale from 1999 to 2003 personal assistant to the CEO at Deutsche Apotheker und Ärtzebank EG from 1998 to 1999 project manager at Mitchell Madison Group from 1996 to 1998 consultant and project manager at Monitor Company from 1993 to 1996 and lecturer at Universitat Karlsruhe 1991 to 1993. He holds a Ph.D. from Universitat Karlsruhe.
Christoph Ehlers

Christoph Ehlers是Centogene的联合创始人。从2008年到2014年,他一直担任执行管理职务,并于2014年加入我们的董事会,担任监督董事。Ehlers先生是一名律师,于1997年创立Equicore Beteiligungsellschaft GmbH,作为一家专门的咨询和投资工具,协助早期生命科学公司的发展。自1999年以来,Ehlers先生还担任Stiftung Ordnungspolitik(一家领先的欧洲经济智囊团)董事会的两名创始董事会成员之一。作为EquiCore业务的一部分,他担任其他早期投资组合公司的管理职务。任职Equicore公司之前,他曾担任Commerzbank AG的多种职务(从1984年到1996年),包括投资银行、主席办公室和领导西南分支机构。他在康斯坦斯大学(University of Constance)学习法律,1983年被德国律师协会(the German Bar)录取,持有法学硕士学位。来自the University of San Diego Law School。


Christoph Ehlers is a co-founder of Centogene. After having been in the executive management from 2008 to 2014 he joined our board as a supervisory director in 2014. Mr. Ehlers, by profession a lawyer, founded Equicore Beteiligungsgesellschaft GmbH in 1997 as a specialized consulting and investment vehicle to assist in the development of early stage LifeScience companies. Since 1999 Mr. Ehlers has also served as one of two founding board members on the board of Stiftung Ordnungspolitik, a leading European economic think-tank. As part of the Equicore business, he holds management positions in other early stage portfolio companies. Prior to Equicore he held various positions at Commerzbank AG from 1984 to 1996 including functions in investment banking, the Chairman's office and leading the southwestern branches. He studied law at the University of Constance, was admitted in 1983 to the German bar and holds an LL.M. from the University of San Diego Law School.
Christoph Ehlers是Centogene的联合创始人。从2008年到2014年,他一直担任执行管理职务,并于2014年加入我们的董事会,担任监督董事。Ehlers先生是一名律师,于1997年创立Equicore Beteiligungsellschaft GmbH,作为一家专门的咨询和投资工具,协助早期生命科学公司的发展。自1999年以来,Ehlers先生还担任Stiftung Ordnungspolitik(一家领先的欧洲经济智囊团)董事会的两名创始董事会成员之一。作为EquiCore业务的一部分,他担任其他早期投资组合公司的管理职务。任职Equicore公司之前,他曾担任Commerzbank AG的多种职务(从1984年到1996年),包括投资银行、主席办公室和领导西南分支机构。他在康斯坦斯大学(University of Constance)学习法律,1983年被德国律师协会(the German Bar)录取,持有法学硕士学位。来自the University of San Diego Law School。
Christoph Ehlers is a co-founder of Centogene. After having been in the executive management from 2008 to 2014 he joined our board as a supervisory director in 2014. Mr. Ehlers, by profession a lawyer, founded Equicore Beteiligungsgesellschaft GmbH in 1997 as a specialized consulting and investment vehicle to assist in the development of early stage LifeScience companies. Since 1999 Mr. Ehlers has also served as one of two founding board members on the board of Stiftung Ordnungspolitik, a leading European economic think-tank. As part of the Equicore business, he holds management positions in other early stage portfolio companies. Prior to Equicore he held various positions at Commerzbank AG from 1984 to 1996 including functions in investment banking, the Chairman's office and leading the southwestern branches. He studied law at the University of Constance, was admitted in 1983 to the German bar and holds an LL.M. from the University of San Diego Law School.
Holger Friedrich

Holger Friedrich于2017年加入董事会,担任监督董事。自2010年以来,Friedrich先生一直担任Core SE咨询部门的董事总经理。此前,他曾担任SPM Technologies公司(1993年至2003年被SAP公司收购)的主席,以及SAP高级副总裁,IT架构(2003年至2005年)的主席。他曾担任McKinsey公司的合伙人(从2005年到2008年),负责他们的欧洲企业架构实践。从2009年到2010年,他担任Software AG的董事会成员。弗里德里希先生学习计算机科学和德国研究,他是波茨坦大学理论计算机科学研究所(现称为Hasso Plattner研究所)的创始成员之一。


Holger Friedrich joined our board as a supervisory director in 2017. Since 2010 Mr. Friedrich has served as managing director of CORE SE's consulting unit. Prior to this role, he served as chairman of SPM Technologies acquired by SAP from 1993 to 2003 and as SAP senior vice president, IT Architecture, from 2003 to 2005. He served as partner at McKinsey from 2005 to 2008 and was responsible for their European Enterprise Architecture practice. He served as board member at Software AG from 2009 to 2010. Mr. Friedrich studied computer science and German studies and he was one of the founding members of the Institute for Theoretical Computer Science at the University of Potsdam, which is known today as the Hasso Plattner Institute.
Holger Friedrich于2017年加入董事会,担任监督董事。自2010年以来,Friedrich先生一直担任Core SE咨询部门的董事总经理。此前,他曾担任SPM Technologies公司(1993年至2003年被SAP公司收购)的主席,以及SAP高级副总裁,IT架构(2003年至2005年)的主席。他曾担任McKinsey公司的合伙人(从2005年到2008年),负责他们的欧洲企业架构实践。从2009年到2010年,他担任Software AG的董事会成员。弗里德里希先生学习计算机科学和德国研究,他是波茨坦大学理论计算机科学研究所(现称为Hasso Plattner研究所)的创始成员之一。
Holger Friedrich joined our board as a supervisory director in 2017. Since 2010 Mr. Friedrich has served as managing director of CORE SE's consulting unit. Prior to this role, he served as chairman of SPM Technologies acquired by SAP from 1993 to 2003 and as SAP senior vice president, IT Architecture, from 2003 to 2005. He served as partner at McKinsey from 2005 to 2008 and was responsible for their European Enterprise Architecture practice. He served as board member at Software AG from 2009 to 2010. Mr. Friedrich studied computer science and German studies and he was one of the founding members of the Institute for Theoretical Computer Science at the University of Potsdam, which is known today as the Hasso Plattner Institute.
Guido Prehn

Guido Prehn于2017年加入我们的董事会担任监督董事。Prehn先生在私募股权行业拥有超过15年的经验。他目前任职于OmniMed Holding GmbH、Pharmazell GmbH、Calvias GmbH、Everest Topco B.V.、Auerbach Holding AG、Kohlspitz Holding AG、AWK Group和VTU Group的董事会。Prehn先生是DPE Deutsche Private Equity的常务董事,在该公司成立后不久,他于2008年加入该公司。从2002年到2008年,他曾担任Allianz Capital Partners、TPG Capital和Merrill Lynch公司的多种职务。Prehn先生在芝加哥De Paul University和布宜诺斯艾利斯Universidad Argentina de la Empresa的Oestrich-Winkel的欧洲商学院学习工商管理。


Guido Prehn joined our board as supervisory director in 2017. Mr. Prehn has over 15 years of experience in the private equity industry. He currently serves on the boards of Omniamed Holding GmbH, Pharmazell GmbH, Calvias GmbH, Everest TopCo B.V., Auerbach Holding AG, Kohlspitz Holding AG, AWK Group and VTU Group. Mr. Prehn is a managing director of DPE Deutsche Private Equity where he joined in 2008 shortly after its foundation. Between 2002 and 2008 he worked in various positions at Allianz Capital Partners, TPG Capital and Merrill Lynch. Mr. Prehn studied business administration at the European Business School, Oestrich-Winkel, De Paul University Chicago and Universidad Argentina de la Empresa, Buenos Aires.
Guido Prehn于2017年加入我们的董事会担任监督董事。Prehn先生在私募股权行业拥有超过15年的经验。他目前任职于OmniMed Holding GmbH、Pharmazell GmbH、Calvias GmbH、Everest Topco B.V.、Auerbach Holding AG、Kohlspitz Holding AG、AWK Group和VTU Group的董事会。Prehn先生是DPE Deutsche Private Equity的常务董事,在该公司成立后不久,他于2008年加入该公司。从2002年到2008年,他曾担任Allianz Capital Partners、TPG Capital和Merrill Lynch公司的多种职务。Prehn先生在芝加哥De Paul University和布宜诺斯艾利斯Universidad Argentina de la Empresa的Oestrich-Winkel的欧洲商学院学习工商管理。
Guido Prehn joined our board as supervisory director in 2017. Mr. Prehn has over 15 years of experience in the private equity industry. He currently serves on the boards of Omniamed Holding GmbH, Pharmazell GmbH, Calvias GmbH, Everest TopCo B.V., Auerbach Holding AG, Kohlspitz Holding AG, AWK Group and VTU Group. Mr. Prehn is a managing director of DPE Deutsche Private Equity where he joined in 2008 shortly after its foundation. Between 2002 and 2008 he worked in various positions at Allianz Capital Partners, TPG Capital and Merrill Lynch. Mr. Prehn studied business administration at the European Business School, Oestrich-Winkel, De Paul University Chicago and Universidad Argentina de la Empresa, Buenos Aires.
Eric Souetre

Eric Souetre于2017年加入董事会,担任监督董事。在National Institute of Mental Health担任多个研究职位后,Sou&234;tre博士于1990年创立了“Benefit”,这是一家健康经济学的研究和咨询公司,随后于1995年被Quintiles Inc.(美国)收购。他随后担任Quintiles Inc的董事会成员,在那里他负责全球咨询功能。2003年,Sou&234;tre博士共同创立了LabCo(临床实验室网络),并领导该公司成为欧洲领先的董事长兼首席执行官,直到2010年底。他一直担任活跃的董事会成员,直到2015年Labco公司被出售给Cinven公司。Sou&234;tre博士此后共同创立了一家私募股权基金CareVentures,专注于泛欧梦百合服务风险投资。他目前任职于Opera SA公司的董事会。苏博士拥有马赛大学的神经科学博士学位,尼斯医科大学的医学博士学位和巴黎高等商学院的工商管理硕士学位。


Eric Souetre joined our board as a supervisory director in 2017. After various research positions at National Institute of Mental Health, Dr. Souêtre founded "BENEFIT" in 1990 a research and consulting company in health economics subsequently acquired by QUINTILES Inc. (USA in 1995). He then served as a board member at QUINTILES Inc, where he was responsible for the global consulting function. In 2003 Dr. Souêtre co-founded LABCO - a network of clinical laboratories - and led the company to a European leadership as chairman and CEO until late 2010. He remained as an active board member until LABCO was sold to CINVEN in 2015. Dr. Souêtre has since co-founded a private equity fund, Careventures, focused on pan European healthcare service ventures. He currently serves on the board of OPERA SA. Dr. Souêtre holds a Ph.D. in neurosciences by the Marseille University, an M.D. by the Medical University of Nice and an MBA from HEC school of Paris.
Eric Souetre于2017年加入董事会,担任监督董事。在National Institute of Mental Health担任多个研究职位后,Sou&234;tre博士于1990年创立了“Benefit”,这是一家健康经济学的研究和咨询公司,随后于1995年被Quintiles Inc.(美国)收购。他随后担任Quintiles Inc的董事会成员,在那里他负责全球咨询功能。2003年,Sou&234;tre博士共同创立了LabCo(临床实验室网络),并领导该公司成为欧洲领先的董事长兼首席执行官,直到2010年底。他一直担任活跃的董事会成员,直到2015年Labco公司被出售给Cinven公司。Sou&234;tre博士此后共同创立了一家私募股权基金CareVentures,专注于泛欧梦百合服务风险投资。他目前任职于Opera SA公司的董事会。苏博士拥有马赛大学的神经科学博士学位,尼斯医科大学的医学博士学位和巴黎高等商学院的工商管理硕士学位。
Eric Souetre joined our board as a supervisory director in 2017. After various research positions at National Institute of Mental Health, Dr. Souêtre founded "BENEFIT" in 1990 a research and consulting company in health economics subsequently acquired by QUINTILES Inc. (USA in 1995). He then served as a board member at QUINTILES Inc, where he was responsible for the global consulting function. In 2003 Dr. Souêtre co-founded LABCO - a network of clinical laboratories - and led the company to a European leadership as chairman and CEO until late 2010. He remained as an active board member until LABCO was sold to CINVEN in 2015. Dr. Souêtre has since co-founded a private equity fund, Careventures, focused on pan European healthcare service ventures. He currently serves on the board of OPERA SA. Dr. Souêtre holds a Ph.D. in neurosciences by the Marseille University, an M.D. by the Medical University of Nice and an MBA from HEC school of Paris.
Peer M. Schatz

Peer M. Schatz,他于1993年加入公司,并一直担任首席执行官(2004年1月1日以来)。从1993年到2003年,他是首席财务官,并于1998年成为管理委员会的成员。他此前曾是一个瑞士私人管理层收购集团的合伙人,担任Sandoz公司和Computerland公司的金融和系统职务,以及欧洲和美国的各种计算机和软件交易行业的初创企业的金融、业务、管理和销售职位。他于1989年获得the University of St. Gallen(位于瑞士)的金融金融硕士学位,并于1991年获得the University of Chicago Graduate School of Business的金融工商管理硕士学位。直到2008年,他担任Evotec公司的监事会成员。直到2011年,他担任PMS Asset Management GmbH的管理委员会成员。他也曾担任the German Corporate Governance Commission的成员(从2002年到2012年1月)。他是QIAGEN Marseille公司(QIAGEN公司于2011年收购的子公司)的董事会主席。


Peer M. Schatz joined the supervisory board of Centogene in March 2020 as interim member and interim vice-chairman of the supervisory board, subject to approval of the shareholders at the Company's upcoming Annual General Meeting in June 2020. He joins Centogene from his recent position as long-time Chief Executive Officer of QIAGEN N.V. Nasdaq: QGEN; Frankfurt: QIA, a leading provider of molecular sample and assay technologies. From 1993 to 2019 he led QIAGEN's rapid expansion from a start-up company with $2 million in sales into a global leader in molecular testing with over $1.6 billion in revenues. Mr. Schatz also served as a founding member of the German Corporate Governance Commission and as a supervisory board member of Evotec AG (Frankfurt: EVT). Mr. Schatz graduated from the University of St. Gallen, Switzerland with a Masters Degree in Finance and from the University of Chicago Graduate School of Business with an MBA.
Peer M. Schatz,他于1993年加入公司,并一直担任首席执行官(2004年1月1日以来)。从1993年到2003年,他是首席财务官,并于1998年成为管理委员会的成员。他此前曾是一个瑞士私人管理层收购集团的合伙人,担任Sandoz公司和Computerland公司的金融和系统职务,以及欧洲和美国的各种计算机和软件交易行业的初创企业的金融、业务、管理和销售职位。他于1989年获得the University of St. Gallen(位于瑞士)的金融金融硕士学位,并于1991年获得the University of Chicago Graduate School of Business的金融工商管理硕士学位。直到2008年,他担任Evotec公司的监事会成员。直到2011年,他担任PMS Asset Management GmbH的管理委员会成员。他也曾担任the German Corporate Governance Commission的成员(从2002年到2012年1月)。他是QIAGEN Marseille公司(QIAGEN公司于2011年收购的子公司)的董事会主席。
Peer M. Schatz joined the supervisory board of Centogene in March 2020 as interim member and interim vice-chairman of the supervisory board, subject to approval of the shareholders at the Company's upcoming Annual General Meeting in June 2020. He joins Centogene from his recent position as long-time Chief Executive Officer of QIAGEN N.V. Nasdaq: QGEN; Frankfurt: QIA, a leading provider of molecular sample and assay technologies. From 1993 to 2019 he led QIAGEN's rapid expansion from a start-up company with $2 million in sales into a global leader in molecular testing with over $1.6 billion in revenues. Mr. Schatz also served as a founding member of the German Corporate Governance Commission and as a supervisory board member of Evotec AG (Frankfurt: EVT). Mr. Schatz graduated from the University of St. Gallen, Switzerland with a Masters Degree in Finance and from the University of Chicago Graduate School of Business with an MBA.
Hubert Birner

自2005年以来,Hubert Birner担任我们董事会主席。自2001年以来,他担任我们董事会的成员。一家风险资本公司,Argos的子公司。2000年,他担任投资经理。目前,他担任公司的管理合伙人。从1998年到2000年,他担任欧洲业务开发负责人和德国营销董事,捷利康农药公司,一家生物制药公司。加入Zeneca Agrochemicals之前,他担任McKinsey & Company和管理顾问,负责欧洲医疗和制药业务。他目前是Proteon Therapeutics和SpePharm Holdings BV董事会成员。此前,他担任Horizon Pharma、Bioxell SA, Evotec AG 和Jerini AG董事会成员。他拥有哈佛商学院MBA和德国慕尼黑大学生物化学博士学位。他的博士论文因在代谢疾病方面杰出的基础研究被授予Hoffmann-La Roche奖。


Hubert Birner joined the supervisory board of Centogene as Chairman from July 2017 to March 30 2019 and as Vice-Chairman from April 1 2019 to March 16 2020. He currently serves as a managing partner at TVM Capital, and is responsible for its overall investment strategy and fund operations in North American and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently also serves as Chairman of the supervisory board of SpePharm Holding B.V., leon-nanodrugs GmbH and AL-S Pharma AG. He is a member of the board of directors of Argos Therapeutics, Inc., Proteon Therapeutics Inc, Noxxon Pharma and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice and as Assistant Professor for biochemistry at the Ludwig-Maximilian-University "LMU". He holds a summa cum laude doctoral degree in biochemistry at LMU. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.
自2005年以来,Hubert Birner担任我们董事会主席。自2001年以来,他担任我们董事会的成员。一家风险资本公司,Argos的子公司。2000年,他担任投资经理。目前,他担任公司的管理合伙人。从1998年到2000年,他担任欧洲业务开发负责人和德国营销董事,捷利康农药公司,一家生物制药公司。加入Zeneca Agrochemicals之前,他担任McKinsey & Company和管理顾问,负责欧洲医疗和制药业务。他目前是Proteon Therapeutics和SpePharm Holdings BV董事会成员。此前,他担任Horizon Pharma、Bioxell SA, Evotec AG 和Jerini AG董事会成员。他拥有哈佛商学院MBA和德国慕尼黑大学生物化学博士学位。他的博士论文因在代谢疾病方面杰出的基础研究被授予Hoffmann-La Roche奖。
Hubert Birner joined the supervisory board of Centogene as Chairman from July 2017 to March 30 2019 and as Vice-Chairman from April 1 2019 to March 16 2020. He currently serves as a managing partner at TVM Capital, and is responsible for its overall investment strategy and fund operations in North American and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently also serves as Chairman of the supervisory board of SpePharm Holding B.V., leon-nanodrugs GmbH and AL-S Pharma AG. He is a member of the board of directors of Argos Therapeutics, Inc., Proteon Therapeutics Inc, Noxxon Pharma and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice and as Assistant Professor for biochemistry at the Ludwig-Maximilian-University "LMU". He holds a summa cum laude doctoral degree in biochemistry at LMU. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.
Flemming Ornskov

Flemming Ornskov,2013年1月2日,他被任命为董事会成员,2013年4月30日被任命为首席执行官之前是首席执行官指定人。他给董事会带来了经营和医疗知识以及制药业的丰富国际、战略和经营经验。2010至2012年,他担任拜耳General and Speciality Medicine的首席营销官和战略营销全球主管;2008至2010年,担任Bausch & Lomb, Inc.的药物和非处方药全球总裁;2006年至2008年,先后担任Life-Cycle Pharma A/S的主席、总裁和首席执行官,2005至2006年,担任Ikaria, Inc.的总裁和首席执行官。在他的制药职业生涯早期,他就职于默克公司(Merck & Co., Inc.)和诺华制药(Novartis AG),在医院和医学院有辉煌的历史。他曾担任Evotec AG的非执行主席和PCI Biotech Holding ASA的非执行董事。他在哥本哈根大学(University of Copenhagen)获得医学博士学位,在欧洲工商管理学院(INSEAD)获得工商管理学硕士学位并在哈佛大学(Harvard University)获得公共卫生硕士学位。


Flemming Ornskov Chief Executive Officer of Galderma SA, a healthcare company focused on dermatology October 2019 to present, Chief Executive Officer and Board Member of Shire plc (2013 to January 2019), Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG (2010 to 2012), Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. (2008 to 2010), Prior to these assignments, held roles of increasing responsibility at, among others, Merck & Co. Inc. and Novartis AG.
Flemming Ornskov,2013年1月2日,他被任命为董事会成员,2013年4月30日被任命为首席执行官之前是首席执行官指定人。他给董事会带来了经营和医疗知识以及制药业的丰富国际、战略和经营经验。2010至2012年,他担任拜耳General and Speciality Medicine的首席营销官和战略营销全球主管;2008至2010年,担任Bausch & Lomb, Inc.的药物和非处方药全球总裁;2006年至2008年,先后担任Life-Cycle Pharma A/S的主席、总裁和首席执行官,2005至2006年,担任Ikaria, Inc.的总裁和首席执行官。在他的制药职业生涯早期,他就职于默克公司(Merck & Co., Inc.)和诺华制药(Novartis AG),在医院和医学院有辉煌的历史。他曾担任Evotec AG的非执行主席和PCI Biotech Holding ASA的非执行董事。他在哥本哈根大学(University of Copenhagen)获得医学博士学位,在欧洲工商管理学院(INSEAD)获得工商管理学硕士学位并在哈佛大学(Harvard University)获得公共卫生硕士学位。
Flemming Ornskov Chief Executive Officer of Galderma SA, a healthcare company focused on dermatology October 2019 to present, Chief Executive Officer and Board Member of Shire plc (2013 to January 2019), Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG (2010 to 2012), Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. (2008 to 2010), Prior to these assignments, held roles of increasing responsibility at, among others, Merck & Co. Inc. and Novartis AG.
Berndt Modig

Berndt Modig自2015年3月起担任董事会成员。自2016年3月以来,Modig一直担任Pharvaris N.V.的首席执行官,这是一家专注于罕见病的公共临床阶段生物技术公司。从2010年3月起,他担任制药公司Prosensa Holding N.V.的首席财务官,直到2015年1月被BioMarin pharmaceutical Inc.收购。2003年10月至2008年11月,Modig先生担任制药公司Jerini AG的首席财务官,负责私人融资、2005年首次公开募股,并于2008年被Takeda pharmaceutical company收购的生物制药公司Shire plc收购。在此之前,Modig先生于2001年至2003年担任二手工业设备分销商Surplex AG的首席财务官,并于1999年至2001年在总部位于美国的热塑性阀门制造商Hayward Industrial Products Inc.担任欧洲财务总监。Modig先生曾于1994年至1999年担任总部位于Brussels的私募股权公司Agra Industria的合伙人,1991年至1994年担任纽约Financial Services Industry Group of Price Waterhouse LLP的高级经理。Modig目前担任公共临床阶段生物技术公司Pharvaris N.V.的董事。他还担任审计委员会主席和上市生物制药公司Centogene N.V.的董事。此前,他还曾担任(i) Kiadis Pharma n.v.(一家上市生物制药公司)的董事会(2016年6月至2021年4月);(ii) Auris Medical Holding Ltd.(一家制药公司)的董事会(2014年4月至2018年3月);(iii) Affimed n.v.(一家上市生物制药公司)的董事会(2014年9月至2020年8月)。他持有University of Lund的工商管理、经济学和德语学士学位,以及INSEAD, Fontainebleau, France的工商管理硕士学位。他是注册会计师(不活跃)。


Berndt Modig has served as a member of the Board since March 2015. Since March 2016 Mr. Modig has served as Chief Executive Officer of Pharvaris N.V., a public clinical stage biotechnology company focusing on rare diseases. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008 Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005 and its acquisition by Shire plc, a biopharmaceutical company acquired by Takeda Pharmaceutical Company, in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG, a reseller of used industrial equipment, from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc., a thermoplastic valve manufacturer, from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director of Pharvaris N.V., a public clinical stage biotechnology company. He also serves as chair of the audit committee and as a director of Centogene N.V., a public biopharmaceutical company. He also previously served on (i) the board of directors of Kiadis Pharma N.V., a public biopharmaceutical company, from June 2016 to April 2021 (ii) the board of directors of Auris Medical Holding Ltd., a pharmaceutical company, from April 2014 to March 2018 and (iii) the board of directors of Affimed N.V., a public biopharmaceutical company, from September 2014 to August 2020. Mr. Modig received his bachelor's degree in business administration, economics and German from the University of Lund, Sweden and his M.B.A. from INSEAD, Fontainebleau, France and is a Certified Public Accountant (inactive).
Berndt Modig自2015年3月起担任董事会成员。自2016年3月以来,Modig一直担任Pharvaris N.V.的首席执行官,这是一家专注于罕见病的公共临床阶段生物技术公司。从2010年3月起,他担任制药公司Prosensa Holding N.V.的首席财务官,直到2015年1月被BioMarin pharmaceutical Inc.收购。2003年10月至2008年11月,Modig先生担任制药公司Jerini AG的首席财务官,负责私人融资、2005年首次公开募股,并于2008年被Takeda pharmaceutical company收购的生物制药公司Shire plc收购。在此之前,Modig先生于2001年至2003年担任二手工业设备分销商Surplex AG的首席财务官,并于1999年至2001年在总部位于美国的热塑性阀门制造商Hayward Industrial Products Inc.担任欧洲财务总监。Modig先生曾于1994年至1999年担任总部位于Brussels的私募股权公司Agra Industria的合伙人,1991年至1994年担任纽约Financial Services Industry Group of Price Waterhouse LLP的高级经理。Modig目前担任公共临床阶段生物技术公司Pharvaris N.V.的董事。他还担任审计委员会主席和上市生物制药公司Centogene N.V.的董事。此前,他还曾担任(i) Kiadis Pharma n.v.(一家上市生物制药公司)的董事会(2016年6月至2021年4月);(ii) Auris Medical Holding Ltd.(一家制药公司)的董事会(2014年4月至2018年3月);(iii) Affimed n.v.(一家上市生物制药公司)的董事会(2014年9月至2020年8月)。他持有University of Lund的工商管理、经济学和德语学士学位,以及INSEAD, Fontainebleau, France的工商管理硕士学位。他是注册会计师(不活跃)。
Berndt Modig has served as a member of the Board since March 2015. Since March 2016 Mr. Modig has served as Chief Executive Officer of Pharvaris N.V., a public clinical stage biotechnology company focusing on rare diseases. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008 Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005 and its acquisition by Shire plc, a biopharmaceutical company acquired by Takeda Pharmaceutical Company, in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG, a reseller of used industrial equipment, from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc., a thermoplastic valve manufacturer, from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director of Pharvaris N.V., a public clinical stage biotechnology company. He also serves as chair of the audit committee and as a director of Centogene N.V., a public biopharmaceutical company. He also previously served on (i) the board of directors of Kiadis Pharma N.V., a public biopharmaceutical company, from June 2016 to April 2021 (ii) the board of directors of Auris Medical Holding Ltd., a pharmaceutical company, from April 2014 to March 2018 and (iii) the board of directors of Affimed N.V., a public biopharmaceutical company, from September 2014 to August 2020. Mr. Modig received his bachelor's degree in business administration, economics and German from the University of Lund, Sweden and his M.B.A. from INSEAD, Fontainebleau, France and is a Certified Public Accountant (inactive).

高管简历

中英对照 |  中文 |  英文
Arndt Rolfs

Arndt Rolfs是我们的联合创始人之一。他自2014年起担任首席执行官,自2006年起担任首席医疗官。他此前曾于2008年至2018年担任罗斯托克大学阿尔布雷希特-科塞尔神经再生研究所所长。在创立Centogene之前,Rolfs教授从1997年到2008年担任罗斯托克大学神经学中心临床和门诊神经科副主任。他也曾担任the Department of Neurology的高级顾问,以及the University of Rostock的神经生物学研究实验室的负责人(从1993年到2008年)。从1991年到1993年,他曾任职柏林the University Hospital Rudolf-Virchow的精神病诊所。从1989年到1993年,他是柏林自由大学(the Free University of Berlin)神经化学实验室的负责人。Rolfs从1988年到1989年在Max-Planck-Institute for Molecular Genetics任职,从1985年到1988年在柏林自由大学(Free University of Berlin)神经学系任职。Rolfs教授是罕见病领域几个国际流行病学研究的首席研究员,并积极从事几种代谢性疾病的生物标志物研究。他在医学和科学出版物方面有着广泛的往绩记录,是300多份同行评议出版物的作者或贡献者。Rolfs教授于1985年获得美因茨大学(the University of Mainz)的医生认可。


Arndt Rolfs is one of our co-founders. He has served as Chief Executive Officer since 2014 and Chief Medical Officer since 2006. He previously served as Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock from 2008 to 2018. Prior to founding Centogene, Prof. Rolfs was Vice-Director of the Clinic and Outpatients Department for Neurology at the Centre for Neurology, University of Rostock, from 1997 to 2008. He also served as a Senior Consultant at the Department of Neurology and as Head of the Neurobiological Research Laboratory from 1993 to 2008 at the University of Rostock. From 1991 to 1993 he worked at the Psychiatric Clinic at the University Hospital Rudolf-Virchow in Berlin. From 1989 to 1993 he was the Head of the Laboratory for Neurochemistry at the Free University of Berlin. From 1988 to 1989 Prof. Rolfs worked at the Max-Planck-Institute for Molecular Genetics and from 1985 to 1988 at the Department of Neurology at the Free University of Berlin. Prof. Rolfs is the principal investigator of several international epidemiological studies in the area of rare diseases and actively engaged in biomarker research for several metabolic diseases. He has an extensive track record in medical and scientific publications and is the author of or contributor to more than 300 peer-reviewed publications. Prof. Rolfs received his approbation as physician from the University of Mainz in 1985.
Arndt Rolfs是我们的联合创始人之一。他自2014年起担任首席执行官,自2006年起担任首席医疗官。他此前曾于2008年至2018年担任罗斯托克大学阿尔布雷希特-科塞尔神经再生研究所所长。在创立Centogene之前,Rolfs教授从1997年到2008年担任罗斯托克大学神经学中心临床和门诊神经科副主任。他也曾担任the Department of Neurology的高级顾问,以及the University of Rostock的神经生物学研究实验室的负责人(从1993年到2008年)。从1991年到1993年,他曾任职柏林the University Hospital Rudolf-Virchow的精神病诊所。从1989年到1993年,他是柏林自由大学(the Free University of Berlin)神经化学实验室的负责人。Rolfs从1988年到1989年在Max-Planck-Institute for Molecular Genetics任职,从1985年到1988年在柏林自由大学(Free University of Berlin)神经学系任职。Rolfs教授是罕见病领域几个国际流行病学研究的首席研究员,并积极从事几种代谢性疾病的生物标志物研究。他在医学和科学出版物方面有着广泛的往绩记录,是300多份同行评议出版物的作者或贡献者。Rolfs教授于1985年获得美因茨大学(the University of Mainz)的医生认可。
Arndt Rolfs is one of our co-founders. He has served as Chief Executive Officer since 2014 and Chief Medical Officer since 2006. He previously served as Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock from 2008 to 2018. Prior to founding Centogene, Prof. Rolfs was Vice-Director of the Clinic and Outpatients Department for Neurology at the Centre for Neurology, University of Rostock, from 1997 to 2008. He also served as a Senior Consultant at the Department of Neurology and as Head of the Neurobiological Research Laboratory from 1993 to 2008 at the University of Rostock. From 1991 to 1993 he worked at the Psychiatric Clinic at the University Hospital Rudolf-Virchow in Berlin. From 1989 to 1993 he was the Head of the Laboratory for Neurochemistry at the Free University of Berlin. From 1988 to 1989 Prof. Rolfs worked at the Max-Planck-Institute for Molecular Genetics and from 1985 to 1988 at the Department of Neurology at the Free University of Berlin. Prof. Rolfs is the principal investigator of several international epidemiological studies in the area of rare diseases and actively engaged in biomarker research for several metabolic diseases. He has an extensive track record in medical and scientific publications and is the author of or contributor to more than 300 peer-reviewed publications. Prof. Rolfs received his approbation as physician from the University of Mainz in 1985.
Dirk H. Ehlers

DirkH.Ehlers自2018年4月起担任Clinical Diagnostics首席运营官兼总裁。加入我们之前,他曾担任伊利诺伊州芝加哥希尔罗控股公司的高级副总裁和外科解决方案部门总裁,以及集团执行团队成员。2015年至2018年,他是Protagen AG的非执行董事会成员。从2010年到2014年,Ehlers博士担任Eppendorf AG的总裁兼首席执行官。在此之前,他从2007年到2010年担任Hoffmann La Roche专业诊断主管和诊断执行委员会成员。从2001年到2007年,他是Evotec AG的首席财务官和执行董事会成员。从2000年到2001年,Ehlers博士担任Fresenius Kabi AG的执行董事会成员兼肠内营养部总裁。从1995年到2000年,他担任Olympus Europe的诊断系统部门主管。从1989年到1994年,他是麦肯锡公司(McKinsey&Co.)的管理顾问和业务经理。Inc.Ehlers博士拥有硕士学位。他以优异成绩获得亚琛RWTH大学物理学博士学位和物理学博士学位,成绩优异。


Dirk H. Ehlers has served as chief operating officer and president of Clinical Diagnostics since April 2018. Prior to joining us, he served as senior vice president and president of the Surgical Solutions Division and as a member of the Group Executive Team at Hill-Rom Holdings, Inc. in Chicago, Illinois. From 2015 to 2018 he was a non-executive board member of Protagen AG. From 2010 to 2014 Dr. Ehlers served as president and CEO of Eppendorf AG. Prior to that, he served as head of Professional Diagnostics and as a member of the Diagnostics Executive Committee at Hoffmann La Roche from 2007 to 2010. From 2001 to 2007 he was chief financial officer and an executive board member of Evotec AG. From 2000 to 2001 Dr. Ehlers served as an Executive Board member and president of the Enteral Nutrition Division of Fresenius Kabi AG. From 1995 to 2000 he served as Diagnostic Systems Division head at Olympus Europe. From 1989 to 1994 he was a management consultant and an engagement manager at McKinsey & Co. Inc. Dr. Ehlers holds a M.Sc. in Physics and received his Ph.D. in Physics with distinction, summa cum laude, both from the University RWTH in Aachen.
DirkH.Ehlers自2018年4月起担任Clinical Diagnostics首席运营官兼总裁。加入我们之前,他曾担任伊利诺伊州芝加哥希尔罗控股公司的高级副总裁和外科解决方案部门总裁,以及集团执行团队成员。2015年至2018年,他是Protagen AG的非执行董事会成员。从2010年到2014年,Ehlers博士担任Eppendorf AG的总裁兼首席执行官。在此之前,他从2007年到2010年担任Hoffmann La Roche专业诊断主管和诊断执行委员会成员。从2001年到2007年,他是Evotec AG的首席财务官和执行董事会成员。从2000年到2001年,Ehlers博士担任Fresenius Kabi AG的执行董事会成员兼肠内营养部总裁。从1995年到2000年,他担任Olympus Europe的诊断系统部门主管。从1989年到1994年,他是麦肯锡公司(McKinsey&Co.)的管理顾问和业务经理。Inc.Ehlers博士拥有硕士学位。他以优异成绩获得亚琛RWTH大学物理学博士学位和物理学博士学位,成绩优异。
Dirk H. Ehlers has served as chief operating officer and president of Clinical Diagnostics since April 2018. Prior to joining us, he served as senior vice president and president of the Surgical Solutions Division and as a member of the Group Executive Team at Hill-Rom Holdings, Inc. in Chicago, Illinois. From 2015 to 2018 he was a non-executive board member of Protagen AG. From 2010 to 2014 Dr. Ehlers served as president and CEO of Eppendorf AG. Prior to that, he served as head of Professional Diagnostics and as a member of the Diagnostics Executive Committee at Hoffmann La Roche from 2007 to 2010. From 2001 to 2007 he was chief financial officer and an executive board member of Evotec AG. From 2000 to 2001 Dr. Ehlers served as an Executive Board member and president of the Enteral Nutrition Division of Fresenius Kabi AG. From 1995 to 2000 he served as Diagnostic Systems Division head at Olympus Europe. From 1989 to 1994 he was a management consultant and an engagement manager at McKinsey & Co. Inc. Dr. Ehlers holds a M.Sc. in Physics and received his Ph.D. in Physics with distinction, summa cum laude, both from the University RWTH in Aachen.
Richard Stoffelen

Richard Stoffelen自2016年起担任首席财务官“首席财务官”。他在专注于金融、治理和风险管理的国际角色方面拥有超过30年的经验。加入我们之前,他曾担任Holcim Group Services公司的内部审计主管(2013年至2016年)。从2000年到2013年,他曾担任KPMG公司的多种审计和管理职务,在那里他曾负责多种行业的客户审计,包括制药行业。Stoffelen先生毕业于荷兰NBA和蒂尔堡大学(Tilburg University)的荷兰特许会计师,并在哈佛商学院(Harvard Business School),欧洲工商管理学院(INSEAD),国际管理发展学院(IMD)和IESE商学院(IESE Business School)进修高管教育课程。


Richard Stoffelen has served as chief financial officer "CFO" since 2016. He has over 30 years of experience in international roles focused on finance, governance and risk management. Prior to joining us, he was head of Internal Audit at Holcim Group Services from 2013 to 2016. From 2000 to 2013 Mr. Stoffelen worked in various audit and management positions as a partner at KPMG, where he was responsible for audits of clients in a wide variety of industries, including the pharmaceutical industry. Mr. Stoffelen graduated as a Dutch chartered accountant with the NBA and Tilburg University in the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), the IMD and the IESE business school.
Richard Stoffelen自2016年起担任首席财务官“首席财务官”。他在专注于金融、治理和风险管理的国际角色方面拥有超过30年的经验。加入我们之前,他曾担任Holcim Group Services公司的内部审计主管(2013年至2016年)。从2000年到2013年,他曾担任KPMG公司的多种审计和管理职务,在那里他曾负责多种行业的客户审计,包括制药行业。Stoffelen先生毕业于荷兰NBA和蒂尔堡大学(Tilburg University)的荷兰特许会计师,并在哈佛商学院(Harvard Business School),欧洲工商管理学院(INSEAD),国际管理发展学院(IMD)和IESE商学院(IESE Business School)进修高管教育课程。
Richard Stoffelen has served as chief financial officer "CFO" since 2016. He has over 30 years of experience in international roles focused on finance, governance and risk management. Prior to joining us, he was head of Internal Audit at Holcim Group Services from 2013 to 2016. From 2000 to 2013 Mr. Stoffelen worked in various audit and management positions as a partner at KPMG, where he was responsible for audits of clients in a wide variety of industries, including the pharmaceutical industry. Mr. Stoffelen graduated as a Dutch chartered accountant with the NBA and Tilburg University in the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), the IMD and the IESE business school.
Volkmar Weckesser

Volkmar Weckesser自2016年起担任首席信息官。加入我们之前,他曾担任Gothaer Systems GmbH的首席执行官兼集团首席信息官(2014年至2016年)。他曾担任执行委员会成员2009年至2014年担任DeKabank Deutsche Girozentrale的信息技术主管从2003年到2009年担任HSH Nordbank AG信息技术部门的中央部门经理,从1999年到2003年担任Landesbank Schleswig-Holstein Girozentrale的部门经理,从1998年到1999年担任Deutsche Apotheker und&196;RTZebank EG的首席执行官个人助理Mitchell Madison Group的项目经理1996年至1998年Monitor Company顾问和项目经理(1993年至1996年)和Universitat Karlsruhe讲师(1991年至1993年)。他持有Universitat Karlsruhe的博士学位。


Volkmar Weckesser has served as chief information officer since 2016. Prior to joining us, he served as chief executive officer and group chief information officer at Gothaer Systems GmbH from 2014 to 2016. He served as a Member of the Executive Council and head of Information Technology at Dekabank Deutsche Girozentrale from 2009 to 2014 as a central division manager of the Information Technology Division of HSH Nordbank AG from 2003 to 2009 division manager of Landesbank Schleswig-Holstein Girozentrale from 1999 to 2003 personal assistant to the CEO at Deutsche Apotheker und Ärtzebank EG from 1998 to 1999 project manager at Mitchell Madison Group from 1996 to 1998 consultant and project manager at Monitor Company from 1993 to 1996 and lecturer at Universitat Karlsruhe 1991 to 1993. He holds a Ph.D. from Universitat Karlsruhe.
Volkmar Weckesser自2016年起担任首席信息官。加入我们之前,他曾担任Gothaer Systems GmbH的首席执行官兼集团首席信息官(2014年至2016年)。他曾担任执行委员会成员2009年至2014年担任DeKabank Deutsche Girozentrale的信息技术主管从2003年到2009年担任HSH Nordbank AG信息技术部门的中央部门经理,从1999年到2003年担任Landesbank Schleswig-Holstein Girozentrale的部门经理,从1998年到1999年担任Deutsche Apotheker und&196;RTZebank EG的首席执行官个人助理Mitchell Madison Group的项目经理1996年至1998年Monitor Company顾问和项目经理(1993年至1996年)和Universitat Karlsruhe讲师(1991年至1993年)。他持有Universitat Karlsruhe的博士学位。
Volkmar Weckesser has served as chief information officer since 2016. Prior to joining us, he served as chief executive officer and group chief information officer at Gothaer Systems GmbH from 2014 to 2016. He served as a Member of the Executive Council and head of Information Technology at Dekabank Deutsche Girozentrale from 2009 to 2014 as a central division manager of the Information Technology Division of HSH Nordbank AG from 2003 to 2009 division manager of Landesbank Schleswig-Holstein Girozentrale from 1999 to 2003 personal assistant to the CEO at Deutsche Apotheker und Ärtzebank EG from 1998 to 1999 project manager at Mitchell Madison Group from 1996 to 1998 consultant and project manager at Monitor Company from 1993 to 1996 and lecturer at Universitat Karlsruhe 1991 to 1993. He holds a Ph.D. from Universitat Karlsruhe.
Oved Amitay

Oved Amitay自2018年11月起担任我们的首席商务官,在此之前,他于2016年至2018年担任Arrett Neuroscience的总裁兼首席运营官,领导公司开发Rett综合征疗法的战略。在担任该职位之前,他曾于2012年至2016年担任Alnylam Pharmaceuticals的商业主管Vice President,并在该组织从以技术平台为中心向以患者为中心的药物开发和上市前企业转型的过程中发挥领导作用。Amitay从1998年到2011年在健赞公司(Sanofi Genzyme)(现为Sanofi Genzyme)担任战略发展Vice President,负责罕见遗传病专营权的项目管理、业务开发、市场评估和业务规划,并担任Gaucher and MPS业务总经理。他也是以色列SpliSense Therapeutics公司的创始顾问,在那里他曾担任该职务(2016年至今)。Amitay先生拥有马萨诸塞州波士顿东北大学(Northeastern University)的药理学硕士学位和以色列耶路撒冷希伯来大学(Hebrew University)的药学学士学位。


Oved Amitay has served as our chief business officer since November 2018 prior to which he held the position of president and chief operating officer of Arrett Neuroscience from 2016 to 2018 having led the company's strategy for developing therapies for Rett syndrome. Prior to this role, he served as Vice President, Head of Commercial at Alnylam Pharmaceuticals from 2012 to 2016 with a lead role in the organization's transition from a technology-platform focus to a patient-centric drug development and pre-launch enterprise. Mr. Amitay had a long tenure at Genzyme Corporation now Sanofi Genzyme from 1998 to 2011 as Vice President, Strategic Development, responsible for program management, business development, market assessment and business planning for the rare genetic diseases franchise, and as General Manager of the Gaucher and MPS business. He is also a Founding Advisor of Splisense Therapeutics, Israel, where he held this role from 2016 to present. Mr. Amitay holds a M.Sc., Pharmacology, from Northeastern University, Boston, MA and a B.Sc., Pharmacy, from the Hebrew University, Jerusalem, Israel.
Oved Amitay自2018年11月起担任我们的首席商务官,在此之前,他于2016年至2018年担任Arrett Neuroscience的总裁兼首席运营官,领导公司开发Rett综合征疗法的战略。在担任该职位之前,他曾于2012年至2016年担任Alnylam Pharmaceuticals的商业主管Vice President,并在该组织从以技术平台为中心向以患者为中心的药物开发和上市前企业转型的过程中发挥领导作用。Amitay从1998年到2011年在健赞公司(Sanofi Genzyme)(现为Sanofi Genzyme)担任战略发展Vice President,负责罕见遗传病专营权的项目管理、业务开发、市场评估和业务规划,并担任Gaucher and MPS业务总经理。他也是以色列SpliSense Therapeutics公司的创始顾问,在那里他曾担任该职务(2016年至今)。Amitay先生拥有马萨诸塞州波士顿东北大学(Northeastern University)的药理学硕士学位和以色列耶路撒冷希伯来大学(Hebrew University)的药学学士学位。
Oved Amitay has served as our chief business officer since November 2018 prior to which he held the position of president and chief operating officer of Arrett Neuroscience from 2016 to 2018 having led the company's strategy for developing therapies for Rett syndrome. Prior to this role, he served as Vice President, Head of Commercial at Alnylam Pharmaceuticals from 2012 to 2016 with a lead role in the organization's transition from a technology-platform focus to a patient-centric drug development and pre-launch enterprise. Mr. Amitay had a long tenure at Genzyme Corporation now Sanofi Genzyme from 1998 to 2011 as Vice President, Strategic Development, responsible for program management, business development, market assessment and business planning for the rare genetic diseases franchise, and as General Manager of the Gaucher and MPS business. He is also a Founding Advisor of Splisense Therapeutics, Israel, where he held this role from 2016 to present. Mr. Amitay holds a M.Sc., Pharmacology, from Northeastern University, Boston, MA and a B.Sc., Pharmacy, from the Hebrew University, Jerusalem, Israel.
Peter Bauer

Peter Bauer自2019年12月以来一直担任我们的首席基因组官,在此之前,他于2017年1月至2019年11月担任我们的首席科学官,并于2016年加入我们以来担任首席运营官。鲍尔教授是宾根大学(University of T&252;Bingen)的人类遗传学教授,是一位获得委员会认证的人类遗传学家,在分子遗传学,诊断测试,遗传咨询,遗传变体的功能验证以及用于临床测序医学解释的生物信息学工具方面具有专业知识。加入我们之前,他曾担任the Institute of Medical Genetics and Applied Genomics,University Hospital T&252;Bingen的诊断和研究实验室主管(从2001年到2015年)。鲍尔教授自2004年以来一直是德国神经遗传学学会的Vice President。Bauer教授在柏林自由大学(Freie University Berlin)获得医学学位,并于1998年在柏林医师委员会(Board of Physicians)获得医师德国官方执业许可。


Peter Bauer has served as our chief genomic officer since December 2019 prior to which he served as our chief scientific officer from January 2017 to November 2019 and chief operating officer since joining us in 2016. Prof. Bauer is a professor of human genetics at the University of Tübingen and a board-certified human geneticist with expertise in molecular genetics, diagnostic testing, genetic counselling, functional validation of genetic variants and bioinformatics tools for medical interpretation of clinical sequencing. Prior to joining us, he served as head of the diagnostic and research laboratory at the Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen from 2001 to 2015. Prof. Bauer has been vice president of the German Society of Neurogenetics since 2004. Prof. Bauer received a degree in medicine from the Freie University Berlin and the approbation as physician German official license to practice medicine from the Board of Physicians in Berlin in 1998.
Peter Bauer自2019年12月以来一直担任我们的首席基因组官,在此之前,他于2017年1月至2019年11月担任我们的首席科学官,并于2016年加入我们以来担任首席运营官。鲍尔教授是宾根大学(University of T&252;Bingen)的人类遗传学教授,是一位获得委员会认证的人类遗传学家,在分子遗传学,诊断测试,遗传咨询,遗传变体的功能验证以及用于临床测序医学解释的生物信息学工具方面具有专业知识。加入我们之前,他曾担任the Institute of Medical Genetics and Applied Genomics,University Hospital T&252;Bingen的诊断和研究实验室主管(从2001年到2015年)。鲍尔教授自2004年以来一直是德国神经遗传学学会的Vice President。Bauer教授在柏林自由大学(Freie University Berlin)获得医学学位,并于1998年在柏林医师委员会(Board of Physicians)获得医师德国官方执业许可。
Peter Bauer has served as our chief genomic officer since December 2019 prior to which he served as our chief scientific officer from January 2017 to November 2019 and chief operating officer since joining us in 2016. Prof. Bauer is a professor of human genetics at the University of Tübingen and a board-certified human geneticist with expertise in molecular genetics, diagnostic testing, genetic counselling, functional validation of genetic variants and bioinformatics tools for medical interpretation of clinical sequencing. Prior to joining us, he served as head of the diagnostic and research laboratory at the Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen from 2001 to 2015. Prof. Bauer has been vice president of the German Society of Neurogenetics since 2004. Prof. Bauer received a degree in medicine from the Freie University Berlin and the approbation as physician German official license to practice medicine from the Board of Physicians in Berlin in 1998.
Sun Kim

Sun Kim自2019年5月起担任我们的首席战略和投资者关系官。在被任命之前,金先生于2018年8月至2019年4月担任Shire plc公司战略主管,在那里他还负责Shire plc在美国的投资者关系活动,并于2017年10月至2018年8月担任投资者关系Vice President。在加入Shire plc之前,他曾于2015年3月至2017年9月担任诺华全球卓越商业服务主管,2013年7月至2015年3月担任爱尔康新加坡总经理,2011年9月至2013年7月担任爱尔康全球战略主管。2009年8月至2011年9月,Kim先生还在Bausch&Lomb工作,领导其制药业务单元的战略职能。在他在制药行业的经验之前,Kim先生在麦肯锡公司(McKinsey&Company)和A.T.Kearney担任了七年的管理顾问。Kim先生拥有斯坦福大学(Stanford University)化学工程博士学位和硕士学位,以及首尔国立大学(Seoul National University)化学工程学士学位。


Sun Kim has served as our chief strategy and investor relations officer since May 2019. Prior to his appointment, Mr. Kim was Head of Corporate Strategy at Shire Plc from August 2018 to April 2019 where he also oversaw Shire Plc's investor relations activities in the US and, from October 2017 to August 2018 he was Vice President, Investor Relations. Prior to joining Shire Plc, he served as Global Head of Business Service Excellence at Novartis from March 2015 to September 2017 as General Manager at Alcon Singapore from July 2013 to March 2015 and as Global Head of Strategy for Alcon from September of 2011 to July 2013. Mr. Kim also worked at Bausch & Lomb from August 2009 to September 2011 heading up its strategy function for the pharmaceutical business unit. Prior to his experience in the pharmaceutical industry, Mr. Kim spent seven years as a Management Consultant at McKinsey & Company and A.T. Kearney. Mr. Kim holds a Ph.D. and M.S. in chemical engineering from Stanford University, and B.S. in chemical engineering from Seoul National University.
Sun Kim自2019年5月起担任我们的首席战略和投资者关系官。在被任命之前,金先生于2018年8月至2019年4月担任Shire plc公司战略主管,在那里他还负责Shire plc在美国的投资者关系活动,并于2017年10月至2018年8月担任投资者关系Vice President。在加入Shire plc之前,他曾于2015年3月至2017年9月担任诺华全球卓越商业服务主管,2013年7月至2015年3月担任爱尔康新加坡总经理,2011年9月至2013年7月担任爱尔康全球战略主管。2009年8月至2011年9月,Kim先生还在Bausch&Lomb工作,领导其制药业务单元的战略职能。在他在制药行业的经验之前,Kim先生在麦肯锡公司(McKinsey&Company)和A.T.Kearney担任了七年的管理顾问。Kim先生拥有斯坦福大学(Stanford University)化学工程博士学位和硕士学位,以及首尔国立大学(Seoul National University)化学工程学士学位。
Sun Kim has served as our chief strategy and investor relations officer since May 2019. Prior to his appointment, Mr. Kim was Head of Corporate Strategy at Shire Plc from August 2018 to April 2019 where he also oversaw Shire Plc's investor relations activities in the US and, from October 2017 to August 2018 he was Vice President, Investor Relations. Prior to joining Shire Plc, he served as Global Head of Business Service Excellence at Novartis from March 2015 to September 2017 as General Manager at Alcon Singapore from July 2013 to March 2015 and as Global Head of Strategy for Alcon from September of 2011 to July 2013. Mr. Kim also worked at Bausch & Lomb from August 2009 to September 2011 heading up its strategy function for the pharmaceutical business unit. Prior to his experience in the pharmaceutical industry, Mr. Kim spent seven years as a Management Consultant at McKinsey & Company and A.T. Kearney. Mr. Kim holds a Ph.D. and M.S. in chemical engineering from Stanford University, and B.S. in chemical engineering from Seoul National University.
Philip Lambert

Philip Lambert自2019年12月起担任我们的首席科学官。在被任命之前,Lambert博士是生命生物科学公司Discovery and Labs的高级副总裁,该公司是一家全球性公司,致力于通过调查被认为能延长寿命的八种生物途径来延长个人的健康寿命。他还担任Selphagy Therapeutics和Spotlight Biosciences的首席运营官,这是Life Biosciences的子公司。任职Life Biosciences公司之前,他曾担任Charles River Laboratories的科学合伙人兼发现主管,在那里他负责建立科学信誉,并将业务交付给客户公司和风险投资公司。他还联合创立了Vivopath,一家临床前筛选公司,为客户提供概念验证测试的发现和开发服务。他持有Imperial College,University of London的神经药理学博士学位,以及the University of Liverpool的药理学学士学位。


Philip Lambert has served as our chief scientific officer since December 2019. Prior to his appointment, Dr. Lambert was Senior Vice President of Discovery and Labs of Life Biosciences, a global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He also served as Chief Operating Officer of Selphagy Therapeutics and Spotlight Biosciences, subsidiaries of Life Biosciences. Prior to Life Biosciences, Dr. Lambert served as Scientific Partner and Head of Discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms. He also co-founded VivoPath, a preclinical screening company, offering clients discovery and development services for proof-of-concept testing. He holds a PhD in Neuropharmacology from Imperial College, University of London and a BSc in Pharmacology from the University of Liverpool.
Philip Lambert自2019年12月起担任我们的首席科学官。在被任命之前,Lambert博士是生命生物科学公司Discovery and Labs的高级副总裁,该公司是一家全球性公司,致力于通过调查被认为能延长寿命的八种生物途径来延长个人的健康寿命。他还担任Selphagy Therapeutics和Spotlight Biosciences的首席运营官,这是Life Biosciences的子公司。任职Life Biosciences公司之前,他曾担任Charles River Laboratories的科学合伙人兼发现主管,在那里他负责建立科学信誉,并将业务交付给客户公司和风险投资公司。他还联合创立了Vivopath,一家临床前筛选公司,为客户提供概念验证测试的发现和开发服务。他持有Imperial College,University of London的神经药理学博士学位,以及the University of Liverpool的药理学学士学位。
Philip Lambert has served as our chief scientific officer since December 2019. Prior to his appointment, Dr. Lambert was Senior Vice President of Discovery and Labs of Life Biosciences, a global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He also served as Chief Operating Officer of Selphagy Therapeutics and Spotlight Biosciences, subsidiaries of Life Biosciences. Prior to Life Biosciences, Dr. Lambert served as Scientific Partner and Head of Discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms. He also co-founded VivoPath, a preclinical screening company, offering clients discovery and development services for proof-of-concept testing. He holds a PhD in Neuropharmacology from Imperial College, University of London and a BSc in Pharmacology from the University of Liverpool.